1. Aqueous extract of Spirulina exerts neuroprotection in an experimental model of Alzheimer sporadic disease in mice induced by Streptozotocin.
- Author
-
Tavares J, Oliveira AV, de Souza Nascimento T, Gomes JMP, Parente ACB, Bezerra JR, da Costa MDR, de Aguiar MSS, Sampaio TL, Lima FAV, de Barros Viana GS, and de Andrade GM
- Subjects
- Animals, Male, Mice, Oxidative Stress drug effects, Plant Extracts pharmacology, Plant Extracts therapeutic use, Brain drug effects, Brain metabolism, Brain pathology, Hippocampus drug effects, Hippocampus metabolism, Hippocampus pathology, Spirulina chemistry, Streptozocin, Alzheimer Disease drug therapy, Alzheimer Disease metabolism, Alzheimer Disease chemically induced, Neuroprotective Agents pharmacology, Neuroprotective Agents therapeutic use, Disease Models, Animal
- Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disease that causes gradual memory loss and cognitive impairment. Intracerebroventricular injections of streptozotocin (ICV-STZ) have been used as an experimental model of sporadic Alzheimer's disease (SAD) because they produce deficits in brain insulin signaling, oxidative stress, neuroinflammation, and neurodegeneration, resulting in cognitive decline and memory impairment. Spirulina platensis (SPI) is a nutraceutical with anti-inflammatory, antioxidant, and neuroprotective properties. The objective of this work was to study the effects of SPI on cognitive deficits and neuronal damage in mice submitted to the experimental model of SAD induced by ICV-STZ. Male Swiss mice (25-35 g) received ICV-STZ (3 mg/Kg) bilaterally on days 1 and 3, SPI (50 and 100 mg/Kg, o.p.) or vehicle (saline) was administered 2 h after the second surgery, and once a day for 16 days. SPI treatment prevented working, episodic, spatial, and aversive memory deficits. Locomotor activity was not altered. ICV-STZ caused an increase in MDA, nitrite, and superoxide anion, while decreasing GSH. SPI treatment protected against GSH increase in the prefrontal cortex and hippocampus, and inhibited AChE activity in the prefrontal cortex. SPI prevented astrogliosis and microgliosis induced by ICV-STZ. These findings highlight the therapeutic potential of SPI for the treatment of SAD, indicating that its neuroprotective action is linked to antioxidant, anti-inflammatory, and AChE inhibitory activity., Competing Interests: Declarations. Ethics committee: All procedures in this study are in accordance with the Guide for the Care and Use of Laboratory Animals of the US Health and Human Services Department and were approved by the ethics committee in animal experimentation of the Federal University of Ceará, under registration number 3598100320. Consent to participate: Not applicable. Competing interests: The authors declare no competing interests., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF